Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


A novel treatment for heart failure targets myocardial fibrosis

A new trial suggests that pirfenidone, an approved treatment for idiopathic pulmonary fibrosis, may also reduce myocardial fibrosis in patients with heart failure who have a preserved left ventricular ejection fraction.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Pathways that lead to myocardial fibrosis.


  1. 1.

    Lewis, G. A. et al. Nat. Med. (2021).

    Article  Google Scholar 

  2. 2.

    Cleland, J. G. F. et al. Eur. Heart J. 42, 2331–2343 (2021).

    Article  Google Scholar 

  3. 3.

    Pellicori, P. et al. Eur. J. Heart Fail. (2021).

    Article  PubMed  Google Scholar 

  4. 4.

    Pellicori, P. et al. Eur. J. Heart Fail. 22, 1711–1723 (2020).

    CAS  Article  Google Scholar 

  5. 5.

    Pellicori, P. et al. Cardiovasc. Res. 116, 91–100 (2020).

    CAS  Article  Google Scholar 

  6. 6.

    Cleland, J. G. F. et al. Eur. Heart J. 39, 26–35 (2018).

    CAS  Article  Google Scholar 

  7. 7.

    Cleland, J. G. F. et al. Eur. Heart J. 42, 684–696 (2020).

    Article  Google Scholar 

  8. 8.

    Gonzalez, A., Schelbert, E. B., Diez, J. & Butler, J. J. Am. Coll. Cardiol. 71, 1696–1706 (2018).

    Article  Google Scholar 

  9. 9.

    Aimo, A. et al. Pharmacol. Res. 155, 104694 (2020).

    CAS  Article  Google Scholar 

  10. 10.

    Lopez, B. et al. J. Am. Coll. Cardiol. 67, 251–260 (2016).

    CAS  Article  Google Scholar 

  11. 11.

    Lopez, B. et al. Nat. Rev. Cardiol. 18, 479–498 (2021).

    Article  Google Scholar 

  12. 12.

    Mason, T. et al. JACC Cardiovasc. Imaging 14, 1164–1173 (2021).

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to John G. F. Cleland.

Ethics declarations

Competing interests

J.G.F.C. has received research funding from Torrent Pharmaceuticals, which has an advanced glycation-end-product breaker in development.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cleland, J.G.F., Pellicori, P. & González, A. A novel treatment for heart failure targets myocardial fibrosis. Nat Med 27, 1343–1344 (2021).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing